Tezacaftor/Ivacaftor
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
7 The tezacaftor/ivacaftor combination has been evaluated in a large Phase III program enrolling cystic fibrosis patients with a wide range of genotypes, including at least one copy of the F508del mutation. Having come through these trials successfully, Vertex filed for regulatory approval in the US in August 2017, with expected first approval in February 2018 (Vertex, 2017a).
The combination of a CFTR corrector and potentiator has already been established in Vertex’s other marketed cystic fibrosis therapy, Orkambi. However, the replacement of lumacaftor with tezacaftor has been shown to be effective in both homozygous and certain heterozygous F508del mutations (Vertex, 2017b). Orkambi is currently only approved for homozygous F508del cystic fibrosis patients (Orkambi prescribing information, 2016).
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 tezacaftor/ivacaftor : Cystic fibrosis
LIST OF FIGURES
9 Figure 1: Tezacaftor/ivacaftor for cystic fibrosis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary for tezacaftor/ivacaftor in cystic fibrosis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary for tezacaftor /ivacaftor in cystic fibrosis
LIST OF TABLES
5 Table 1: Tezacaftor/ivacaftor drug profile
7 Table 2: Tezacaftor/ivacaftor Phase III data in cystic fibrosis
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Colobreathe 
Sign up to the